Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 1.80
ACUR's Cash to Debt is ranked higher than
73% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.36 vs. ACUR: 1.80 )
ACUR' s 10-Year Cash to Debt Range
Min: 0   Max: No Debt
Current: 1.8

Equity to Asset 0.47
ACUR's Equity to Asset is ranked higher than
57% of the 750 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.59 vs. ACUR: 0.47 )
ACUR' s 10-Year Equity to Asset Range
Min: -7.86   Max: 0.97
Current: 0.47

-7.86
0.97
F-Score: 2
Z-Score: -21.94
M-Score: 238.62
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -7078.97
ACUR's Operating margin (%) is ranked lower than
56% of the 782 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.55 vs. ACUR: -7078.97 )
ACUR' s 10-Year Operating margin (%) Range
Min: -11455.28   Max: 51.47
Current: -7078.97

-11455.28
51.47
Net-margin (%) -7290.26
ACUR's Net-margin (%) is ranked lower than
56% of the 782 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.93 vs. ACUR: -7290.26 )
ACUR' s 10-Year Net-margin (%) Range
Min: -11301.63   Max: 50.74
Current: -7290.26

-11301.63
50.74
ROE (%) -85.81
ACUR's ROE (%) is ranked lower than
53% of the 792 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.26 vs. ACUR: -85.81 )
ACUR' s 10-Year ROE (%) Range
Min: -61.03   Max: 51.89
Current: -85.81

-61.03
51.89
ROA (%) -59.92
ACUR's ROA (%) is ranked lower than
53% of the 811 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.06 vs. ACUR: -59.92 )
ACUR' s 10-Year ROA (%) Range
Min: -1207.97   Max: 33.14
Current: -59.92

-1207.97
33.14
ROC (Joel Greenblatt) (%) -1303.25
ACUR's ROC (Joel Greenblatt) (%) is ranked lower than
52% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.08 vs. ACUR: -1303.25 )
ACUR' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1243.6   Max: 1569.92
Current: -1303.25

-1243.6
1569.92
Revenue Growth (%) -100.00
ACUR's Revenue Growth (%) is ranked lower than
56% of the 671 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.10 vs. ACUR: -100.00 )
ACUR' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 27.3
Current: -100

0
27.3
EBITDA Growth (%) 2.40
ACUR's EBITDA Growth (%) is ranked higher than
69% of the 640 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.20 vs. ACUR: 2.40 )
ACUR' s 10-Year EBITDA Growth (%) Range
Min: -60.2   Max: 144.4
Current: 2.4

-60.2
144.4
EPS Growth (%) 2.40
ACUR's EPS Growth (%) is ranked higher than
72% of the 625 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.00 vs. ACUR: 2.40 )
ACUR' s 10-Year EPS Growth (%) Range
Min: -84.9   Max: 56.5
Current: 2.4

-84.9
56.5
» ACUR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

ACUR Guru Trades in

ACUR Guru Trades in

ACUR Guru Trades in

Q2 2014

ACUR Guru Trades in Q2 2014

Jim Simons 12,700 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with ACUR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 3.71
ACUR's P/B is ranked higher than
69% of the 833 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.39 vs. ACUR: 3.71 )
ACUR' s 10-Year P/B Range
Min: 0.92   Max: 15.82
Current: 3.71

0.92
15.82
EV-to-EBIT -2.22
ACUR's EV-to-EBIT is ranked lower than
55% of the 833 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 31.14 vs. ACUR: -2.22 )
ACUR' s 10-Year EV-to-EBIT Range
Min: 0.2   Max: 63
Current: -2.22

0.2
63
Current Ratio 7.87
ACUR's Current Ratio is ranked higher than
93% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.28 vs. ACUR: 7.87 )
ACUR' s 10-Year Current Ratio Range
Min: 0.02   Max: 68.17
Current: 7.87

0.02
68.17
Quick Ratio 7.69
ACUR's Quick Ratio is ranked higher than
94% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.74 vs. ACUR: 7.69 )
ACUR' s 10-Year Quick Ratio Range
Min: 0.01   Max: 68.17
Current: 7.69

0.01
68.17

Valuation & Return

vs
industry
vs
history
Price/Net Cash 6.50
ACUR's Price/Net Cash is ranked higher than
95% of the 833 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. ACUR: 6.50 )
ACUR' s 10-Year Price/Net Cash Range
Min: 2.81   Max: 112
Current: 6.5

2.81
112
Price/Net Current Asset Value 6.50
ACUR's Price/Net Current Asset Value is ranked higher than
93% of the 833 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. ACUR: 6.50 )
ACUR' s 10-Year Price/Net Current Asset Value Range
Min: 2.76   Max: 112
Current: 6.5

2.76
112
Price/Tangible Book 4.59
ACUR's Price/Tangible Book is ranked higher than
72% of the 833 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.72 vs. ACUR: 4.59 )
ACUR' s 10-Year Price/Tangible Book Range
Min: 2.64   Max: 80
Current: 4.59

2.64
80
Forward Rate of Return (Yacktman) -7.69
ACUR's Forward Rate of Return (Yacktman) is ranked higher than
59% of the 668 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.86 vs. ACUR: -7.69 )
ACUR' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -65.7   Max: -1.9
Current: -7.69

-65.7
-1.9

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:HD4A.Germany
Acura Pharmaceuticals, Inc. is a specialty pharmaceutical company engaged in the research, development and commercialization of products intended to address medication abuse and misuse, utilizing its proprietary Aversion and Impede Technologies. Its products and product candidates are based on widely-used commercial products and do not alter the safety and efficacy of the active pharmaceutical ingredients. Its product, Oxecta, or Oxecta (formerly Acurox), was approved for marketing by the United States Food and Drug Administration, or FDA, on June 17, 2011. Oxecta represents the first immediate-release oxycodone product approved by the FDA that applies to its Aversion Technology. Aversion is a mixture of inactive ingredients incorporated into pharmaceutical tablets and capsules designed to address some common methods of product tampering associated with abuse. Oxecta will be manufactured and commercialized by Pfizer under its October 2007 license agreement with a subsidiary of Pfizer. In addition to Oxecta, it has licensed to Pfizer the rights to develop, manufacture and commercialize three other immediate-release opioid products utilizing Aversion Technology in the United States, Canada and Mexico, including: hydrocodone bitartrate /acetaminophen tablets; oxycodone HCl / acetaminophen tablets; and an undisclosed opioid analgesic tablet product. Such potential competitors include, but may not be limited to, Pain Therapeutics, in collaboration with Pfizer, Purdue Pharma, Atlantic Pharmaceuticals, Egalet a/s, KemPharm and Collegium Pharmaceuticals, Inc. The company is subject to extensive regulation by the federal government, principally by the FDA under the Federal Food, Drug and Cosmetic Act, or the FD&C Act, and, to a lesser extent, by state and local governments. The company's portfolio of product candidates includes opioid analgesics intended to effectively relieve pain while simultaneously discouraging common methods of pharmaceutical product misuse and abuse including: intravenous injection of dissolved tablets or capsules, nasal snorting of crushed tablets or capsules, and intentional swallowing of excess quantities of tablets or capsules.
» More Articles for ACUR

Headlines

Articles On GuruFocus.com
Acura Pharmaceuticals Inc. Reports Operating Results (10-K) Mar 01 2011 
Acura Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 02 2010 
Acura Pharmaceuticals Inc. Reports Operating Results (10-Q) Jul 29 2010 
Acura Pharmaceuticals Inc. Reports Operating Results (10-Q) Oct 26 2009 
Acura Pharmaceuticals Inc. Reports Operating Results (10-Q) Jul 30 2009 
Acura Pharmaceuticals Inc. Reports Operating Results (10-Q) May 01 2009 
American Honda Reports 2008 Annual and December Monthly Sales Jan 05 2009 
Acura Announces December and 2008 Year-End Sales Results Jan 05 2009 


More From Other Websites
ACURA PHARMACEUTICALS, INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued... Sep 18 2014
Impax Rytary FDA Action Date Extended by Three Months Sep 18 2014
ACURA PHARMACEUTICALS, INC Files SEC form 8-K, Other Events Sep 15 2014
Acura Pharmaceuticals Submits Formal Dispute Resolution Request With FDA Regarding Hydrocodone... Sep 15 2014
Acura Pharmaceuticals Receives Grant From National Institutes of Health to Fund Limitx(TM) Novel... Aug 27 2014
FDA seeks more data on Acura's abuse-resistant pain drug Aug 15 2014
ACURA PHARMACEUTICALS, INC Files SEC form 8-K, Other Events Aug 15 2014
Acura Pharmaceuticals Provides Update on FDA Discussions Surrounding Development of Aversion... Aug 15 2014
ACURA PHARMACEUTICALS, INC Financials Aug 12 2014
ACURA PHARMACEUTICALS, INC Files SEC form 8-K, Results of Operations and Financial Condition,... Aug 04 2014
ACURA PHARMACEUTICALS, INC Files SEC form 10-Q, Quarterly Report Aug 04 2014
Acura Pharmaceuticals Announces Second Quarter 2014 Financial Results Aug 04 2014
Acura Pharmaceuticals to Host Second Quarter 2014 Financial Results Conference Call on August 5,... Jul 24 2014
Acura Pharmaceuticals Inc Stock Downgraded (ACUR) Jun 03 2014
Acura Pharma downgraded to Hold from Buy at MLV & Co. May 28 2014
ACURA PHARMACEUTICALS, INC Files SEC form 8-K, Other Events May 27 2014
Acura Pharma provides update on AP-ADF-301 May 27 2014
Acura Pharmaceuticals Provides Update on Its Abuse Deterrent Hydrocodone/Acetaminophen Combination... May 27 2014
Acura Pharma trading halted, pending news May 27 2014
Novartis Settles Litigation Agreement with Acura May 23 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK